Coagulation Consultants Competitors

As part of the Duke University School of Medicine, the Duke Clinical Research Institute (DCRI) is known globally for conducting groundbreaking multinational trials, managing major national patient registries, and performing landmark research. As an academic clinical research organization, we combine the faculty expertise of practicing physicians with the full-service operational capabilities of a major CRO. We design and implement innovative clinical trials that advance the understanding of health and disease and inform efforts to improve the quality of care. Our experience stretches from phase I to phase IV and beyond, encompassing post-approval analyses and health economics. The breadth of our work in numerous therapeutic areas is matched by the depth of our knowledge, which we disseminate through high-impact publications and global meetings. Since 1996, DCRI's faculty and staff have disseminated over 17,500 peer-reviewed publications and have been cited in over 760,500 scientific articles.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.